These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Choosing antibiotic therapy for severe community-acquired pneumonia. Martin-Loeches I; Garduno A; Povoa P; Nseir S Curr Opin Infect Dis; 2022 Apr; 35(2):133-139. PubMed ID: 35190510 [TBL] [Abstract][Full Text] [Related]
5. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Prina E; Ranzani OT; Polverino E; Cillóniz C; Ferrer M; Fernandez L; Puig de la Bellacasa J; Menéndez R; Mensa J; Torres A Ann Am Thorac Soc; 2015 Feb; 12(2):153-60. PubMed ID: 25521229 [TBL] [Abstract][Full Text] [Related]
6. Guidelines for severe community-acquired pneumonia in the western world. Vegelin AL; Bissumbhar P; Joore JC; Lammers JW; Hoepelman IM Neth J Med; 1999 Sep; 55(3):110-7. PubMed ID: 10509069 [TBL] [Abstract][Full Text] [Related]
7. Severe community-acquired pneumonia treated with β-lactam-respiratory quinolone vs. β-lactam-macrolide combination. Karhu J; Ala-Kokko TI; Ohtonen P; Syrjälä H Acta Anaesthesiol Scand; 2013 May; 57(5):587-93. PubMed ID: 23379766 [TBL] [Abstract][Full Text] [Related]
8. Risk factors for drug-resistant pathogens in immunocompetent patients with pneumonia: Evaluation of PES pathogens. Ishida T; Ito A; Washio Y; Yamazaki A; Noyama M; Tokioka F; Arita M J Infect Chemother; 2017 Jan; 23(1):23-28. PubMed ID: 27729192 [TBL] [Abstract][Full Text] [Related]
9. Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. Ceccato A; Mendez R; Ewig S; de la Torre MC; Cilloniz C; Gabarrus A; Prina E; Ranzani OT; Ferrer M; Almirall J; Menendez R; Torres A Ann Am Thorac Soc; 2021 Feb; 18(2):257-265. PubMed ID: 32915057 [No Abstract] [Full Text] [Related]
10. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Torres A; Cillóniz C; Ferrer M; Gabarrús A; Polverino E; Villegas S; Marco F; Mensa J; Menéndez R; Niederman M Eur Respir J; 2015 May; 45(5):1353-63. PubMed ID: 25614173 [TBL] [Abstract][Full Text] [Related]
11. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. Bassetti M; Russo A; Cilloniz C; Giacobbe DR; Vena A; Amaro R; Graziano E; Soriano A; Torres A Int J Antimicrob Agents; 2020 Apr; 55(4):105921. PubMed ID: 32061999 [TBL] [Abstract][Full Text] [Related]
12. Guideline adherence for empirical treatment of pneumonia and patient outcome. Treating pneumonia in the Netherlands. Huijts SM; van Werkhoven CH; Boersma WG; Buijs J; Buunk G; Compaijen CJ; van Elde LJ; Gisolf JE; van der Kam R; Kluytmans JA; Kuipers BA; Mager JJ; Oppedijk B; Palmen F; Prins JM; van Reemst B; Silbermann MH; van Tiel FH; van der Wall E; van der Werf TS; Bonten MJ Neth J Med; 2013 Dec; 71(10):502-7. PubMed ID: 24394734 [TBL] [Abstract][Full Text] [Related]
13. Current guidelines for the treatment of severe pneumonia and sepsis. Bodmann KF Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664 [TBL] [Abstract][Full Text] [Related]
14. Minor criteria of Infectious Disease Society Of America/American Thoracic Society for severe community-acquired pneumonia can predict delayed treatment response. Park SY; Park S; Lee MG; Kim DG; Suh GY; Kim C; Lee CY; Park YB; Jung KS J Korean Med Sci; 2012 Aug; 27(8):907-13. PubMed ID: 22876058 [TBL] [Abstract][Full Text] [Related]
15. Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection. Wongsurakiat P; Chitwarakorn N BMC Pulm Med; 2019 Oct; 19(1):179. PubMed ID: 31619219 [TBL] [Abstract][Full Text] [Related]
16. Selection of an appropriate empiric antibiotic regimen in hematogenous vertebral osteomyelitis. Park KH; Kim DY; Lee YM; Lee MS; Kang KC; Lee JH; Park SY; Moon C; Chong YP; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Ryu BH; Bae IG; Cho OH PLoS One; 2019; 14(2):e0211888. PubMed ID: 30735536 [TBL] [Abstract][Full Text] [Related]
17. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Chalmers JD; Taylor JK; Mandal P; Choudhury G; Singanayagam A; Akram AR; Hill AT Clin Infect Dis; 2011 Sep; 53(6):503-11. PubMed ID: 21865188 [TBL] [Abstract][Full Text] [Related]
18. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults. Welte T; Kantecki M; Stone GG; Hammond J Int J Antimicrob Agents; 2019 Oct; 54(4):410-422. PubMed ID: 31404620 [TBL] [Abstract][Full Text] [Related]
19. New guidelines for severe community-acquired pneumonia. Martin-Loeches I; Torres A Curr Opin Pulm Med; 2021 May; 27(3):210-215. PubMed ID: 33405483 [TBL] [Abstract][Full Text] [Related]
20. Real life management of community-acquired Pneumonia in adults in the Gulf region and comparison with practice guidelines: a prospective study. Mahboub B; Al Zaabi A; Al Ali OM; Ahmed R; Niederman MS; El-Bishbishi R BMC Pulm Med; 2015 Sep; 15():112. PubMed ID: 26424530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]